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been quantiﬁed adopting the perspective of the third party payer,
i.e. the National Health Service. To determine cost-effectiveness,
we calculated the incremental cost-effectiveness ratio (ICER) as
the ratio of the difference in costs between ODP and PP to the
difference in number-of-bleedings. The nonparametric bootstrap
procedure was employed to generate Conﬁdence Intervals (CIs).
A cost-effectiveness plane and an acceptability curve were
created. The cost-effectiveness acceptability curve represents the
probability that Prophylactic treatment with Refacto® is cost-
effective at all possible values of the maximum acceptable CER
appropriate for decision-making. RESULTS: Nineteen patients,
aged 23–58 years (mean = 33.2) with a mean of 2.97
events/patient/month (median = 1.67, range: 0.5–15) were
enrolled. The incremental-costs of PT versus ODT was estimated
to be €11,619/month (95%CI €7649–15,589) with an additional
effect of 2.49 bleeding-avoided/month (1.06–3.93). The cost-
effectiveness was estimated to be €5184 per bleeding avoided
(€1071–9297). If the ceiling CER is €4500 per bleeding-avoided,
there is a 50% chance that PT is cost-effective. The likelihood
of PT being cost-effective increases to 95% with a ceiling ratio
of €9000/bleeding-avoided. CONCLUSIONS: These ﬁndings
showed prophylaxis with Refacto® in adults with haemophilia
was effective. Our cost-effectiveness results can represent the
point of reference for other similar evaluations.
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OBJECTIVE: To examine characteristics, length of stay (LOS),
and costs associated with trauma-related hospital admissions
with and without blood transfusions. METHODS: The 2003
Health care Cost and Utilization Project database was used to
examine short-stay acute-care hospital discharges for trauma
among adults with and without transfusions. This dataset
includes all discharges from 995 hospitals in 35 states in the U.S.
Trauma discharges were identiﬁed using ICD-9-CM diagnosis
and E-codes; evidence of transfusion was inferred from proce-
dure codes. Patient-level information included demographics,
hospital characteristics, comorbidities, primary payer, admission
source, discharge destination, estimated loss of function (ELOF),
LOS, and hospital charges. Costs were estimated by applying
hospital-speciﬁc cost-to-charge ratios to charges. Determinants
of LOS and cost were assessed through multivariate least-squares
regression. LOS and costs were log-transformed prior to the mul-
tivariate analyses and retransformation following estimation was
undertaken employing the smearing method developed by Duan
and colleagues. RESULTS: Of the 263,816 trauma-related dis-
charges in 2003, 28,859 (11%) had evidence of blood transfu-
sion. Patients with transfusion were more likely than those
without transfusion to be female (68% vs. 52% without hem-
orrhage), aged 65+ years (78% vs. 47%), major or extreme
ELOF (46% vs. 19%), and to die in hospital (6% vs. 2%). After
adjusting for covariates and retransformation, patients with
transfusion, on average, stayed 1.8 more days and cost an addi-
tional $5400 (both p < 0.01). Signiﬁcant predictors (all p < 0.01)
of increased cost included male gender; Hispanic and Asian 
(vs. white) race; care at large, urban, and teaching hospitals; 
coverage by private (vs. public) payer, admission through the
emergency room, increased ELOF, and in-hospital mortality. 
Predictors of decreased cost included older age, black (vs. white)
race, and Midwest region (vs. Northeast). CONCLUSION:
Trauma patients with transfusion account for a disproportion-
ate share of inpatient trauma-related resource use and cost.
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OBJECTIVES: To estimate the incremental hospital costs 
and related length of stay associated with the development of
thrombocytopenia in a general medical/surgical population.
METHODS: We included patients from the Complications After
Thrombocytopenia Caused by Heparin (CATCH) Registry
treated with heparin for ≥96 hours (n = 1997). Hospital costs
for all CATCH patients were estimated using hospital cost
accounting system results for CATCH Registry patients enrolled
at Duke University Medical Center (n = 336). After adjusting 
for baseline characteristics, and procedures and complications
occurring before 96 hours, we estimated incremental hospital
costs associated with thrombocytopenia deﬁned prospectively by
a platelet count drop to <150 × 103/mm3, a platelet count reduc-
tion >50% from admission level, or both. RESULTS: Overall,
28% of CATCH patients receiving heparin for ≥96 hours devel-
oped thrombocytopenia. These patients more commonly had a
history of MI (23% vs. 15%), heart failure (29% vs. 24%), and
experienced more in-hospital death (5.1% vs. 1.1%) than
patients who did not develop thrombocytopenia. The total pop-
ulation’s average length of stay was 14.5 days with mean hospi-
tal costs of $29,523, but both values were signiﬁcantly greater
among patients developing thrombocytopenia (18.0 vs. 13.2
days, and $45,192 vs. $23,527). After adjustment, the develop-
ment of thrombocytopenia in all groups remained a signiﬁcant
marker for increased hospital costs over patients without throm-
bocytopenia (incremental costs = $5262 in patients with a
platelet count drop to <150 × 103/mm3, $9340 in patients with
a platelet count reduction >50% from admission level, and
$18,488 in patients meeting both criteria). CONCLUSIONS:
The incremental economic impact of thrombocytopenia, experi-
enced commonly among hospitalized patients, is substantial.
Strategies that minimize or effectively prevent the development
of thrombocytopenia may therefore be economically attractive.
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OBJECTIVES: Cancer patients receiving chemotherapy com-
monly experience hematologic adverse events (AEs) which
increase the costs of care. This study examined the economic out-
comes of neutropenia, thrombocytopenia, and anemia as AEs of
chemotherapy treatment. METHODS: A systematic search of
the medical literature (1990–2006) was conducted for each AE
using costs/economics as search terms. Additional searches were
conducted from article bibliographies and conference proceed-
ings (2000–2006). Articles selected were prospective or retro-
spective studies speciﬁcally designed to examine burden of
illness, direct medical costs, or cost drivers associated with hema-
tologic AEs in adult cancer patients undergoing chemotherapy.
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RESULTS: Of 290 abstracts screened, 65 met selection criteria
and were reviewed in detail. The average direct medical costs
associated with chemotherapy-induced AEs ranged from
$8,400–$13,500 for neutropenia hospitalization, $5,300–
$7,500 per thrombocytopenia episode, and $14,500–>$114,000
annually for anemia. Key cost drivers for each AE were: neu-
tropenia—hospital length of stay, antibiotics, growth factors,
and diagnostic tests; thrombocytopenia—platelet transfusions
and major bleeding episodes; anemia—EPO-type drugs and
transfusions. Neutropenia and anemia events in patients with
hematologic malignancies resulted in direct medical costs more
than double compared to solid tumors. Indirect costs were >50%
of the direct costs. CONCLUSIONS: Hematologic AEs from
cancer treatments result in substantial economic burden for
payers, patients, and society. This burden appears particularly
heavy for the hematologic malignancies where chemotherapy-
induced hematologic AEs represent >20% of the overall cost of
treatment. Targeted therapies for hematologic malignancy offer
superior outcomes to chemotherapy with reduced AEs. However,
the hematologic toxicities of these targeted agents vary and may
affect the total cost of treatment of the underlying disease. There-
fore, in addition to treatment outcomes, AEs and the cost of
treating AEs should be taken into consideration when determin-
ing the optimal treatment for patients.
PHM5
ECONOMIC ANALYSIS OF SURGICAL INTERVENTIONS IN
ROMANIAN HAEMOPHILIACS
Mihailov MD1, Serban M2, Badeti R3, Popescu B4,Tepeneu P5,
Schramm W6
1University Of Medicine and Pharmacy “Victor Babes”,Timisoara,
Timis, Romania, 2University of Medicine and Pharmacy,Timisoara,
Romania, 3Children Hospital,Timisoara, Romania, 4Children Hopsital,
Timisoara, Romania, 5University of Medicine and Pharmacy “Vitctor
Babes”Timisoara,Timisoara, Romania, 6“Ludwig-Maximillians”—
University, Munich, GA, Germany
In Romanian haemophiliacs, because of limited access to 
clotting factor concentrates, surgical interventions are made
especially in case of severe, life-threatening complications.
OBJECTIVE: To realize an economic analysis of orthopedic and
surgical interventions. METHODS: In a seven-year period, 37
haemophiliacs (from 224 haemophilia patients registered and
treated in Haemophilia Centre Timisoara) underwent 54 surgi-
cal and orthopedic interventions. We evaluated: direct medical
costs (therapy and hospitalization costs) of these interventions,
direct non-medical costs (home-hospital travel costs), indirect
costs (morbidity costs; loss of income of family members who
forfeit paid employment for haemophiliac home care; average
number of days off at school or work), treatment compliance.
Data were obtained from patients’ medical charts and from 
questionnaires administered to patients. RESULTS: Therapy
costs represented 91.14% of direct medical costs (85.8% 
in haemophilia A without high-titer inhibitors, 95.34% in
haemophilia A with high-titer inhibitors and 92.52% in
haemophilia B patients). Direct non-medical costs represented
high percents of mean patient and family income. Mean monthly
morbidity cost was €97.5 and loss of income of family members
who forfeid employment in order to offer home care for
haemophilia patients was €115.04/month. Average number of
days off at school/work was 72.59/year. CONCLUSIONS: Insuf-
ﬁcient resources lead to severe complications in haemophiliacs,
which can be life-threatening, requiring costly surgical interven-
tions. In the absence of home therapy programs and of Com-
prehensive Haemophilia Care Centers, patients have to travel
long home-hospital distances to a hospital where they can receive
treatment, delaying substitution administration, which is also
responsible for complications appearance. Poor social integra-
tion of patients has a negative impact on personal income, affect-
ing treatment compliance. It is therefore necessary a better
resource allocation for haemophilia treatment, in order to
increase direct medical costs and also to offer a better social pro-
tection of the patients.
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OBJECTIVES: For estimating the cost-effectiveness of interven-
tions to avert blood-transfusions it is important to estimate the
costs of one unit of allogeneic blood. An example of such an
intervention is administration of erythropoietin. Objective of this
study was estimating the costs per unit of erythrocytes in The
Netherlands from a societal perspective. METHODS: For the
estimation of the costs we followed the path from donor to
patient. In this path 6 steps were elaborated: donation, produc-
tion, transport, storage and preparation, administration and the
consequences of administration. In these different steps the cost-
consequences were estimated. RESULTS: Although not all cost-
factors could yet be identiﬁed, the cost-estimate is €240, for a
unit of erythrocytes. The indirect costs are responsible for
approximately 3% of the unit costs. The production and trans-
port part by the Dutch blood banks is responsible for the major-
ity of the costs. CONCLUSIONS: Internationally cost-estimates
vary widely. Cost-estimates for the United States, UK, Sweden
and Canada vary from approximately €130 to €930. For The
Netherlands we estimated the unit costs for a unit of erythro-
cytes at €240 from a societal perspective.
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OBJECTIVE: Patients with β-Thalassemia Major (TM) require
life-long blood transfusions and, to avoid iron overload, Iron
Chelation Treatment (ICT), based on 8–12 hour infusions of
Deferoxamine (DFO) for 5–7 days/week, and/or Deferiprone
(L1) orally administered. ICT regimen often causes low satisfac-
tion and low compliance, with potentially negative consequences
on patients’ health, wellbeing and costs. Aims: to investigate
direct costs of treatment in TM patients. Costs were estimated
from the societal perspective, using tariffs or prices applied in
2006. METHODS: The Italian-THAlassemia-Cost-&-Out-
comes-Assessment (ITHACA) was a naturalistic multicentre
study conducted to evaluate costs, quality of life, compliance and
treatment satisfaction in TM patients undergoing ICT. Patients
of any age, on ICT for at least 3 years, were sequentially enrolled
at 8 Italian Thalassemia Care Centers. Data on direct costs are
referred to a retrospective median observational period of 11.7
